Grading allergic ocular disease

Article

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Eiichi Uchio and colleagues from Fukuoka University School of Medicine, Japan created a number of criteria for classifying and clinically evaluating the severity of allergic ocular diseases. They then evaluated the effectiveness of the criteria in the diagnosis of 1,079 patients.

The researchers diagnosed and classified allergic conjunctivitis, atopic keratoconjunctivitis and vernal keratoconjunctivitis based on local and systemic clinical findings. Ten objective conjunctival, limbal and corneal lesion findings were graded on a four-point scale. The total score was used as the clinical score, with a highest value of 30.

Of the 1,079 subjects, 876 (81.2%) were diagnosed with seasonal allergic conjunctivitis, 115 (10.7%) with perennial allergic conjunctivitis, 47 (4.4%) with atopic keratoconjunctivitis and 41 (3.8%) with vernal keratoconjunctivitis. The total clinical scores were 1.54 in seasonal allergic conjunctivitis, 2.13 in perennial allergic conjunctivitis, 3.72 in atopic keratoconjunctivitis and 12.68 in vernal keratoconjunctivitis.

The authors concluded that re-evaluation of allergic ocular disease is necessary for building future strategies for its treatment.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.